Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

9.23
-0.5100-5.24%
Post-market: 9.270.0420+0.46%18:55 EDT
Volume:477.03K
Turnover:4.48M
Market Cap:158.30M
PE:-0.74
High:9.69
Open:9.65
Low:9.19
Close:9.74
52wk High:25.50
52wk Low:9.19
Shares:17.15M
Float Shares:14.99M
Volume Ratio:1.16
T/O Rate:3.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:0.71
PE(LYR):-0.63

Loading ...

Tonix announces second major managed Medicare payer agreement for TONMYA

TIPRANKS
·
Sep 22

Tonix Signs Second Managed Medicare Agreement for Tonmya, Adding 21 Million Covered Lives

Reuters
·
Sep 22

Tonix Pharmaceuticals - Tonmya Medicare Coverage NOW Totals 32 Mln Lives in the U.S. (58%)

THOMSON REUTERS
·
Sep 22

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for Tonmya®

THOMSON REUTERS
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)

TIPRANKS
·
Sep 15

Tonix Pharmaceuticals Files Form 3 for Chief Commercial Officer Thomas Englese

Reuters
·
Sep 08

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

THOMSON REUTERS
·
Sep 08

Tonix Highlights Tonmya Fibromyalgia Launch, Pipeline Progress in Investor Presentation

Reuters
·
Sep 03

Tonix CEO Seth Lederman Acquires 2,000 Common Shares for $27,580

Reuters
·
Aug 31

Tonix Pharma Director Richard H. Bagger Acquires Common Shares Worth $12,600

Reuters
·
Aug 24

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 24

Tonix Names CEO Seth Lederman Interim Chief Medical Officer

Reuters
·
Aug 19

Tonix Pharmaceuticals: Stronger-Than-Expected Tonmya Launch, Expanded Market Access, and Advancing Pipeline Underpin Buy Rating

TIPRANKS
·
Aug 11

Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James

TIPRANKS
·
Aug 11

Tonix Pharmaceuticals Holding Corp. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

Tonix Pharmaceuticals reports Q2 EPS ($2.44), consensus ($2.62)

TIPRANKS
·
Aug 10

Tonix Q2 Revenue Rises Sharply on Tonmya Launch

Reuters
·
Aug 10

Tonix Q2 FY26 Net Loss Narrows to $40.55 Million; Product Revenue Rises to $13.54 Million

Reuters
·
Aug 10

Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate

Benzinga Earnings
·
Aug 10

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

THOMSON REUTERS
·
Aug 10